The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
| 2 | H03 | Thyroid therapy | |
| 3 | H03A | Thyroid preparations | |
| 4 | H03AA | Thyroid hormones | |
| 5 | H03AA01 | Levothyroxine sodium |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.15 mg |
| PAREN - Parenteral | 0.15 mg |
| Active Ingredient | Description | |
|---|---|---|
| Levothyroxine |
Levothyroxine sodium is used for the treatment of hypothyroidism. The chief action of levothyroxine is to increase the rate of cell metabolism. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ELTROXIN Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| EUTHYROX Tablet | Marketing Authorisation Holder | MPI, EU: SmPC | |
| LEVOXYL Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| OROXINE Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| SYNTHROID Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| TIROSINT Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
